Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Reyes (Santiago , Chile), S. Saavedra (Santiago , Chile), K. Vergara (Santiago , Chile), P. Wurmann (Santiago , Chile). Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF. 3396

Member's Comments

No comment yet.

Related content which might interest you: Interstitial lung disease (ILD) in patients with polymyositis/dermatomyositis (PM/DM): clinical features and response to treatment in 6 cases Source: Eur Respir J 2001; 18: Suppl. 33, 528s Year: 2001 Predictors of progression in systemic sclerosis patients with interstitial lung disease Source: Eur Respir J, 55 (5) 1902026; 10.1183/13993003.02026-2019 Year: 2020 Disease course and outcome of progressive interstitial lung disease in systemic sclerosis Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019 Clinical manifestations of systemic sclerosis (SS) accompanied with pulmonary involvement Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Clinical characteristics of interstitial lung fibrosis in progressive systemic sclerosis Source: Eur Respir J 2006; 28: Suppl. 50, 95s Year: 2006 Characterization of interstitial pneumonia associated with clinical amyopathic dermatomyositis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Difference of the clinical characteristics and outcome between interstitial lung disease with dermatomyositis and idiopathic interstitial pneumonia Source: International Congress 2017 – Lung function testing Year: 2017 Clinical features and CT findings of anti-Jo-1 antibody positive interstitial lung disease with or without polymyositis and dermatomyositis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Clinico-laboratory characteristics of patients with interstitial lung disease (ILD) in polymyositis-dermatomyositis (PM/DM) Source: Eur Respir J 2003; 22: Suppl. 45, 46s Year: 2003 Autoantibodies to the surfactant protein D in patients with interstitial lung diseases associated with amyopathic dermatomyositis and systemic sclerosis Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Anti-a-enolase antibodies in systemic sclerosis identify a subset of patients with diffuse cutaneous sclerosis and interstitial lung disease Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 The natural course of systemic sclerosis patients with interstitial lung involvement Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005 Clinical features of interstitial lung disease in polymyositis and dermatomyositis Source: Eur Respir J 2006; 28: Suppl. 50, 828s Year: 2006 Interstitial lung disease in CVID (GLILD): clinical presentation and comparison to CVID without ILD Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment Year: 2019 Interstitial lung disease Source: Eur Respir Rev 2013; 22: 26-32 Year: 2013 Are there any clinical differences between SSc-ILD and UCTD suspected of SSc -ILD? Source: International Congress 2015 – Connective tissue disorders Year: 2015 Interstitial lung disease (ILD) in association with polymyositis-dermatomyositis (PM/DM) with predominant lymphocytic alveolitis and anti-Jo-1-antibodies Source: Eur Respir J 2002; 20: Suppl. 38, 586s Year: 2002 Histology is not a prognostic indicator in patients with interstitial pneumonias associated with systemic sclerosis Source: Eur Respir J 2001; 18: Suppl. 33, 526s Year: 2001 Clinical characteristics of anti-Jo-1-positive interstitial lung disease Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015